MIST: Milestone Pharmaceuticals, Inc.
About
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
Current Value
$1.751 Year Return
Current Value
$1.751 Year Return
Key Details
Market Cap
$92.79M
P/E Ratio
-1.94
1Y Stock Return
-32.56%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
3.9
Strategies that include MIST
Stock's related to MIST
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KRYS | 34.29% | $5.12B | +75.65% | 0.00% |
| CLDX | 32.83% | $1.66B | -10.82% | 0.00% |
| DAVA | 25.81% | $1.16B | -59.28% | 0.00% |
| XMTR | 25.14% | $1.48B | +50.13% | 0.00% |
| ITRI | 25.05% | $5.19B | +76.91% | 0.00% |
| SEG | 24.83% | $319.72M | +12.41% | 0.00% |
| CRSP | 24.13% | $4.01B | -30.49% | 0.00% |
| CSTL | 23.91% | $808.57M | +48.97% | 0.00% |
| ACRS | 23.75% | $327.87M | +415.67% | 0.00% |
| ATUS | 23.31% | $1.10B | -0.42% | 0.00% |
| MARA | 23.01% | $6.39B | +92.63% | 0.00% |
| CRON | 22.88% | $776.06M | 0.00% | 0.00% |
| DMRC | 22.80% | $694.39M | -2.06% | 0.00% |
| SNOW | 22.40% | $43.66B | -21.86% | 0.00% |
| RIOT | 22.13% | $4.08B | +9.85% | 0.00% |
| TNC | 22.12% | $1.61B | -1.42% | 1.31% |
| MX | 22.11% | $135.79M | -45.52% | 0.00% |
| BEAM | 21.66% | $2.09B | -9.52% | 0.00% |
| GYRE | 21.63% | $1.21B | +1.49% | 0.00% |
| AMPH | 21.57% | $2.10B | -23.00% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FARM | -0.01% | $41.47M | -25.00% | 0.00% |
| EPR | 0.01% | $3.38B | -0.51% | 7.62% |
| PAAS | 0.01% | $8.26B | +56.04% | 1.78% |
| INFN | 0.02% | $1.57B | +60.14% | 0.00% |
| PFC | -0.02% | $990.65M | +38.69% | 4.50% |
| AHR | 0.02% | $4.30B | +134.17% | 2.69% |
| ENS | -0.02% | $3.75B | +6.54% | 0.97% |
| SIG | -0.02% | $4.17B | +17.93% | 1.17% |
| BCOV | 0.02% | $133.15M | +17.06% | 0.00% |
| DOUG | 0.04% | $208.46M | +40.12% | 0.00% |
| KRP | -0.04% | $1.29B | +2.58% | 11.03% |
| SD | -0.04% | $430.19M | -10.98% | 3.79% |
| EVGO | -0.05% | $625.86M | +97.63% | 0.00% |
| INNV | -0.05% | $647.47M | -9.13% | 0.00% |
| BZUN | 0.06% | $144.84M | -22.09% | 0.00% |
| ICL | 0.07% | $5.65B | -14.79% | 4.46% |
| NVDA | -0.07% | $3.61T | +194.35% | 0.07% |
| SPT | 0.08% | $1.67B | -46.02% | 0.00% |
| ANGI | 0.08% | $987.36M | -5.71% | 0.00% |
| NWG | -0.09% | $41.67B | +93.64% | 4.45% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HRL | -14.60% | $16.30B | -8.38% | 3.81% |
| NEUE | -13.63% | $40.93M | -34.13% | 0.00% |
| IFF | -13.53% | $22.74B | +20.83% | 2.25% |
| PEN | -12.55% | $9.10B | +2.99% | 0.00% |
| CCEC | -12.16% | $1.02B | +28.03% | 3.26% |
| SOHU | -11.67% | $406.50M | +43.52% | 0.00% |
| EXAS | -11.40% | $9.98B | -17.22% | 0.00% |
| KODK | -11.36% | $422.90M | +41.40% | 0.00% |
| MNST | -11.22% | $52.25B | -1.95% | 0.00% |
| PCG | -10.78% | $44.89B | +18.38% | 0.19% |
| ZTO | -10.66% | $12.58B | -4.71% | 4.73% |
| HLN | -10.55% | $42.91B | +13.94% | 1.67% |
| AMD | -10.53% | $226.20B | +16.98% | 0.00% |
| GDRX | -10.45% | $1.62B | -24.15% | 0.00% |
| UUU | -10.28% | $4.97M | -41.89% | 0.00% |
| UMH | -9.90% | $1.54B | +39.30% | 4.39% |
| MGPI | -9.68% | $1.02B | -48.95% | 1.04% |
| SYPR | -9.44% | $32.23M | -26.32% | 0.00% |
| TCTM | -9.43% | $8.10M | -42.99% | 0.00% |
| CELH | -9.42% | $6.41B | -47.81% | 0.00% |
ETF's related to MIST
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPA | 49.49% | $273.87M | 0% |
| QQA | 31.47% | $135.01M | 0% |
| PBE | 28.20% | $258.53M | 0.58% |
| XBI | 25.87% | $6.58B | 0.35% |
| IBB | 25.42% | $6.66B | 0.45% |
| PTH | 24.04% | $143.31M | 0.6% |
| SMMV | 23.99% | $321.07M | 0.2% |
| BKCH | 23.83% | $204.99M | 0.5% |
| GNOM | 23.27% | $70.59M | 0.5% |
| ARKG | 23.09% | $1.13B | 0.75% |
| XPH | 22.94% | $157.87M | 0.35% |
| FBT | 22.50% | $1.11B | 0.56% |
| IWC | 22.35% | $933.99M | 0.6% |
| IWO | 22.30% | $12.56B | 0.24% |
| PSC | 22.14% | $702.17M | 0.38% |
| BBH | 21.95% | $397.87M | 0.35% |
| XSMO | 21.87% | $1.25B | 0.39% |
| FNY | 21.65% | $372.31M | 0.7% |
| VTWO | 21.60% | $12.38B | 0.1% |
| GSSC | 21.49% | $529.86M | 0.2% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| DFSE | -<0.01% | $306.47M | 0.41% |
| TDTF | -<0.01% | $719.61M | 0.18% |
| STIP | 0.01% | $8.74B | 0.03% |
| SCHE | -0.01% | $9.23B | 0.11% |
| DFEM | -0.03% | $4.21B | 0.39% |
| IBDS | 0.04% | $2.63B | 0.1% |
| DEHP | 0.08% | $202.89M | 0.41% |
| EMGF | 0.08% | $703.16M | 0.25% |
| EPHE | -0.09% | $99.70M | 0.59% |
| CCOR | -0.11% | $109.04M | 1.18% |
| GNR | -0.12% | $2.89B | 0.4% |
| EMQQ | 0.12% | $374.21M | 0.86% |
| LGOV | 0.13% | $607.48M | 0.67% |
| TOTL | -0.14% | $3.31B | 0.55% |
| LDEM | -0.14% | $30.53M | 0.17% |
| PICK | -0.14% | $856.23M | 0.39% |
| EQLS | -0.16% | $76.08M | 1% |
| VGSH | 0.16% | $19.14B | 0.04% |
| BAB | 0.17% | $1.06B | 0.28% |
| TDTT | -0.18% | $1.84B | 0.18% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TPMN | -16.67% | $40.60M | 0.65% |
| BTAL | -13.93% | $388.04M | 1.43% |
| VIXY | -11.09% | $195.31M | 0.85% |
| TAIL | -9.61% | $67.98M | 0.59% |
| ICSH | -8.34% | $5.57B | 0.08% |
| SMB | -8.15% | $266.77M | 0.07% |
| DBB | -7.48% | $126.37M | 0.77% |
| XHLF | -7.13% | $874.27M | 0.03% |
| YEAR | -6.75% | $1.13B | 0.25% |
| IBHD | -6.69% | $327.80M | 0.35% |
| DBO | -6.53% | $217.57M | 0.77% |
| EWS | -6.50% | $560.90M | 0.5% |
| GSG | -6.48% | $914.42M | 0.75% |
| COMT | -6.34% | $829.06M | 0.48% |
| GCC | -6.34% | $133.23M | 0.55% |
| CPER | -6.33% | $159.52M | 0.97% |
| GXC | -6.21% | $433.32M | 0.59% |
| VTIP | -6.21% | $11.71B | 0.04% |
| HIGH | -6.11% | $302.78M | 0.51% |
| VNLA | -6.09% | $2.27B | 0.23% |
News
Yahoo
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Yahoo
MONTREAL (AP) — Milestone Pharmaceuticals Inc. MIST) on Tuesday reported a loss of $9.4 million in its third quarter. The Montreal-based company said it had a loss of 14 cents per share.
Yahoo
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. “Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Mileston
Finnhub
Company Overview Nov 12, 2024 Forward Looking Statement The...
Yahoo
Key Insights The considerable ownership by individual investors in Milestone Pharmaceuticals indicates that they...
Yahoo
Learnings from the Field: Managing PSVT and Studying AFib-RVR in the Community Setting Hosted 10 am ET, Tuesday, October 8, 2024 MONTREAL and CHARLOTTE, N.C., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will host Part 2 of its virtual investor education series on Tuesday, October 8, 2024 from 10:00 AM ET to 11:30 AM ET. To
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.